UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally.
No risks detected for UCB from our risk checks.
Excellent balance sheet with proven track record.
Share Price & News
How has UCB's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: UCB has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: UCB exceeded the Belgian Pharmaceuticals industry which returned 7% over the past year.
Return vs Market: UCB exceeded the Belgian Market which returned -23.8% over the past year.
Price Volatility Vs. Market
How volatile is UCB's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StHere's What UCB SA's (EBR:UCB) Shareholder Ownership Structure Looks Like
1 month ago | Simply Wall StThese 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well
2 months ago | Simply Wall StUCB SA (EBR:UCB) Has Got What It Takes To Be An Attractive Dividend Stock
Is UCB undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: UCB (€102.85) is trading above our estimate of fair value (€70.29)
Significantly Below Fair Value: UCB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: UCB is poor value based on its PE Ratio (26x) compared to the XE Pharmaceuticals industry average (22.1x).
PE vs Market: UCB is poor value based on its PE Ratio (26x) compared to the Belgian market (13.6x).
Price to Earnings Growth Ratio
PEG Ratio: UCB is poor value based on its PEG Ratio (3.7x)
Price to Book Ratio
PB vs Industry: UCB is good value based on its PB Ratio (2.7x) compared to the XE Pharmaceuticals industry average (3.5x).
How is UCB forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: UCB's forecast earnings growth (7.1% per year) is above the savings rate (1.6%).
Earnings vs Market: UCB's earnings (7.1% per year) are forecast to grow slower than the Belgian market (25.6% per year).
High Growth Earnings: UCB's earnings are forecast to grow, but not significantly.
Revenue vs Market: UCB's revenue (1.4% per year) is forecast to grow slower than the Belgian market (5.2% per year).
High Growth Revenue: UCB's revenue (1.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: UCB's Return on Equity is forecast to be low in 3 years time (11.2%).
How has UCB performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UCB has high quality earnings.
Growing Profit Margin: UCB's current net profit margins (14.3%) are higher than last year (13.9%).
Past Earnings Growth Analysis
Earnings Trend: UCB's earnings have grown by 19.4% per year over the past 5 years.
Accelerating Growth: UCB's earnings growth over the past year (13.8%) is below its 5-year average (19.4% per year).
Earnings vs Industry: UCB earnings growth over the past year (13.8%) exceeded the Pharmaceuticals industry 11.2%.
Return on Equity
High ROE: UCB's Return on Equity (10.8%) is considered low.
How is UCB's financial position?
Financial Position Analysis
Short Term Liabilities: UCB's short term assets (€3.1B) exceed its short term liabilities (€2.6B).
Long Term Liabilities: UCB's short term assets (€3.1B) do not cover its long term liabilities (€3.6B).
Debt to Equity History and Analysis
Debt Level: UCB's debt to equity ratio (39.1%) is considered satisfactory.
Reducing Debt: UCB's debt to equity ratio has reduced from 45.2% to 39.1% over the past 5 years.
Debt Coverage: UCB's debt is well covered by operating cash flow (32.7%).
Interest Coverage: UCB's interest payments on its debt are well covered by EBIT (22.4x coverage).
What is UCB current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: UCB's dividend (1.21%) isn’t notable compared to the bottom 25% of dividend payers in the Belgian market (2.56%).
High Dividend: UCB's dividend (1.21%) is low compared to the top 25% of dividend payers in the Belgian market (5.49%).
Stability and Growth of Payments
Stable Dividend: UCB is not paying a notable dividend for the Belgian market, therefore no need to check if payments are stable.
Growing Dividend: UCB is not paying a notable dividend for the Belgian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: UCB is not paying a notable dividend for the Belgian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UCB's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jean-Christophe Tellier (61 yo)
Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively and also was an Interim Chief Financial Officer since ...
CEO Compensation Analysis
Compensation vs Market: Jean-Christophe's total compensation ($USD102.34K) is below average for companies of similar size in the Belgian market ($USD2.52M).
Compensation vs Earnings: Jean-Christophe's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||5.58yrs||€87.00k||no data|
|Executive VP & Chief Scientific Officer||2.83yrs||no data||no data|
|Executive VP & General Counsel||1.42yrs||no data||no data|
|Executive VP & Chief Human Resources Officer||0.50yr||no data||no data|
|Chief Medical Officer||12.42yrs||no data||no data|
|Executive VP of Immunology Solutions & Head of US||5.5yrs||no data||no data|
|Executive VP of Neurology Solutions & Head of EU/International||0.92yr||no data||no data|
|Executive VP & CFO||0.083yr||no data||no data|
|Chief Accounting Officer & CFO of Patient Value Functions||7.42yrs||no data||no data|
|Executive Vice President of Supply & Technology Solutions||0.92yr||no data||no data|
|Head of Investor Relations||10.58yrs||no data||no data|
|Head of Global Communication||no data||no data||no data|
Experienced Management: UCB's management team is considered experienced (2.8 years average tenure).
|CEO & Executive Director||5.58yrs||€87.00k||no data|
|Honorary Chairman||no data||€70.00k||no data|
|Honorary Chairman||15.58yrs||€15.50k||no data|
|Honorary Deputy Chairman||no data||€28.50k||no data|
|Independent Director||10.33yrs||€120.50k||no data|
|Honorary Chairman||no data||€30.00k||no data|
|Honorary Chairman||no data||€49.00k||no data|
|Independent Director||6.33yrs||€137.50k||no data|
|Independent Vice Chairman||3.25yrs||€147.50k||no data|
Experienced Board: UCB's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
UCB SA's company bio, employee growth, exchange listings and data sources
- Name: UCB SA
- Ticker: UCB
- Exchange: ENXTBR
- Founded: 1928
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €19.451b
- Shares outstanding: 189.12m
- Website: https://www.ucb.com
Number of Employees
- UCB SA
- AllEe de la Recherche, 60
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|UCBJ.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Jan 1980|
|UNC||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jan 1980|
|UCB||ENXTBR (Euronext Brussels)||Yes||Common Shares||BE||EUR||Jan 1980|
|0NZT||LSE (London Stock Exchange)||Yes||Common Shares||GB||EUR||Jan 1980|
|UCBB||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||EUR||Jan 1980|
|UCB||WBAG (Wiener Boerse AG)||Yes||Common Shares||AT||EUR||Jan 1980|
|UNC||ETLX (Eurotlx)||Yes||Common Shares||IT||EUR||Jan 1980|
|UCBJ.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADR||US||USD||Feb 2009|
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company’s primary products inc ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/10 20:56|
|End of Day Share Price||2020/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.